Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zicam study

This article was originally published in The Tan Sheet

Executive Summary

Homeopathic remedy found significantly to improve seasonal allergic rhinitis symptoms in a double-blind, placebo-controlled study involving 32 patients, according to Sion Noble, MD, Mission Hills Medical Center, Calif. The peer-reviewed pilot study, published in the August Internet Journal of Family Practice, finds Gum Tech's Zicam Allergy Relief nasal gel improves quality of life for allergic rhinitis sufferers in several categories: activities (social, work, recreational), sleep, emotions, nasal symptoms, ocular symptoms, non-ocular/non-nasal symptoms and practical problems. Quality of life and effect on activity improved 52% and 49.3%, respectively, over the two-week period. NAD recently dismissed an ad challenge involving Zicam cold claims despite concerns regarding substantiation for the claims (1"The Tan Sheet" May 15, In Brief)

You may also be interested in...



NAD dismisses Zicam case

Quigley's use of Gel Tech's submissions to NAD as evidence in its federal court proceeding against Zicam has caused the Council of Better Business Bureaus' National Advertising Division to close its review of Gel Tech's ad claims for Zicam Cold Remedy without issuing a decision. Quigley, the marketer of Cold-Eeze lozenges and challenger of the Zicam claims, violated their confidentiality agreement through its actions, NAD says (1"The Tan Sheet" April 24, p. 8). NAD notes it had "concerns" about whether the claims, including "highly effective cold remedy" and "reduce the duration of the common cold," were adequately supported

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

People In Brief

Perrigo promotes in pricing, planning

Topics

UsernamePublicRestriction

Register

LL1133546

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel